• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

M&As this week: Catalent, Ultragenyx Pharmaceutical

pharmaceufical-technologySeptember 25, 2017

Tag: Catalent , Ultragenyx , pharmaceutical

Catalent has announced plans to acquire Cook Pharmica for $950m.

The acquisition will strengthen Catalent’s position in the biologics development and analytical services sectors.

Both the acquirer and target entities are pharmaceutical companies based in the US.

"Biopharmaceutical company Ultragenyx Pharmaceutical plans to acquire rare disease company Dimension Therapeutics for $138m."

Biopharmaceutical company Ultragenyx Pharmaceutical plans to acquire rare disease company Dimension Therapeutics for $138m.

The acquisition will strengthen the company’s business and help in accelerating the development of its therapeutics.

Both companies involved in the acquisition are based in the US.

Previous:Novartis’ Rydapt receives approval for two cancer treatments in the EU

Next:AbbVie, Bristol-Myers Squibb Announce Clinical Research Collaboration

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

M&As this week: Catalent, Ultragenyx Pharmaceutical | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Pharmaceutical Biotechnology Purified Water Systems

Pharmaceutical Biotechnology Purified Water Systems
Pharmaceutical glass package

Pharmaceutical glass package
Other Active Pharmaceutical Ingredients

Other Active Pharmaceutical Ingredients
Lannaconitine 99%(HPLC) Plant extract Pharmaceutical made in china

Lannaconitine 99%(HPLC) Plant extract Pharmaceutical made in china
Pharmaceutical Low Drying Temperature Vacuum Band Dryer

Pharmaceutical Low Drying Temperature Vacuum Band Dryer
Pantozol CP Pharmaceutical API The digestive system drugs made in china

Pantozol CP Pharmaceutical API The digestive system drugs made in china
CE Approval Laboratory Glassware Washing System in Laboratory and Pharmaceutical Company

CE Approval Laboratory Glassware Washing System in Laboratory and Pharmaceutical Company
Glucose-beta-cyclodextrin pharmaceutical intermediates

Glucose-beta-cyclodextrin pharmaceutical intermediates
Albendazole CP/USP pharmaceutical China supplier for veterinary

Albendazole CP/USP pharmaceutical China supplier for veterinary
Pharmaceutical Grade API Vonoprazan Fumarate CAS 1260141-27-2

Pharmaceutical Grade API Vonoprazan Fumarate CAS 1260141-27-2

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service